



Robert Greene Sterne Jorge A. Goldstein David K.S. Comwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee John M. Covert Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Patrick E. Garrett

Jeffrey T. Helvey Eldora L. Ellison Thomas C. Fiala Donald R. Banowit Peter A. Jackman Jeffrey S. Weaver Brian J. Del Buono Mark Fox Evens Edward W. Yee Vincent L. Capuano Virgil Lee Beaston Theodore A. Wood Flizabeth I. Haanes Joseph S. Ostroff Daniel A. Klein Jason D. Eisenberg October 26, 2006 Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Helene C. Carlson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Bashir M.S. Ali Shannon A. Carroll Anbar F. Khal Michelle K. Holoubek Marsha A. Rose Young Tang

Christopher J. Walsh W. Blake Coblentz* James J. Pohl* John T. Haran Mark W. Rygiel Kevin W. McCabe Michael R. Malek* Doyle A. Siever* Ulrike Winkler*

Registered Patent Agents
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Julie A. Heider
Mita Mukherjee

Scott M. Woodhouse Peter A. Socarras Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

WRITER'S DIRECT NUMBER: (202) 772-8822 INTERNET ADDRESS: SCARROLL@SKGF.COM

Art Unit 1646

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re.

U.S. Utility Patent Application

Application No. 10/648,786; Filed: August 27, 2003 For: **Death Domain Containing Receptor 4**

Inventors:

Ni et al.

Our Ref:

1488.130000B/EJH/SAC

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Reply to Requirement for Election of Species; and
- 2. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

a. Caroll

Shannon A. Carroll, Ph.D. Attorney for Applicants Registration No. 58,240

SAC/rjv Enclosures

Sterne, Kessler, Goldstein & Fox P.L.L.C.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re application of:

Ni et al.

Appl. No.: 10/648,786

Filed: August 27, 2003

For: Death Domain Containing

Receptor 4

Confirmation No.: 5264

Art Unit: 1646

Examiner: Kaufman, C.

Atty. Docket: 1488.130000B/EJH/SAC

Reply to Requirement For Election of Species

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Election of Species Requirement dated September 26, 2006, Applicants hereby provisionally elect to prosecute the following species:

- (A) for the type of antibody: (i) agonist anti-DR4 antibody (claims 1-5, 8-30, 33-56 and 59-77 are readable thereon);
- (B) for the disease to be treated: (6) cancer (claims 26-50 and 75-77 are readable thereon);
- (C) for the second therapeutic agent: (vii) a chemotherapeutic agent (claims 1-19,
- 22, 24-44, 47, 49-68, 71 and 73-77 are readable thereon); and
- (D) for the chemotherapeutic agent: (f) a platinum analog (claims 1-19, 24, 26-44, 49, 51-68, 73 and 75-77 are readable thereon).

These elections are made without prejudice to or disclaimer of the other claims or inventions disclosed.

These elections are made with traverse.

Applicants respectfully submit that to search and examine the subject matter of the method of treating various diseases would not be a serious burden on the Examiner. For example, a search for publications that disclose antibodies which bind Death Domain Containing Receptor-4 (DR4) for treating cancer would lead to publications that disclose antibodies which bind DR4 for treating other diseases. Accordingly, it would not be an undue burden for the Examiner to search all of the various diseases together.

Furthermore, Applicants respectfully submit that to search and examine the subject matter of second therapeutic agents would not be a serious burden on the Examiner. For example, a search for publications that disclose the use of a chemotherapeutic agent for treating disease would lead to publications that disclose the use of other therapeutic agents for treating disease. Accordingly, it would not be an undue burden for the Examiner to search all of the second therapeutic agents together.

Furthermore, Applicants respectfully submit that to search and examine the subject matter of various chemotherapeutic agents would not be a serious burden on the Examiner. For example, a search for publications that disclose the use of a platinum analog for treating disease would lead to publications that disclose the use of other chemotherapeutic agents for treating disease. Accordingly, it would not be an undue burden for the Examiner to search all of the chemotherapeutic agents together.

Finally, in accordance with 37 C.F.R. § 1.141(a), Applicants also reserve the right to claim additional species, and/or to have additional species searched and/or examined, in the event that a generic claim is found to be allowable.

It is believed that extensions of time are not required, beyond those that may otherwise be provided for in accompanying documents. However, in the event that additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any

fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Canon a. Canall

Shannon A. Carroll, Ph.D. Attorney for Applicants Registration No. 58,240

Date: October 26, 2006

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600 596498_1.DOC